查詢結果分析
相關文獻
- 骨髓纖維化病患接受異體造血幹細胞移植之預後:單一中心回溯性研究
- Complicated Urinary Tract Infection: Analysis of 179 Patients
- Influence of Infection on Prognosis of Systemic Lupus Erythematosus Patients Receiving Corticosteroid Treatment
- 顱內膿瘍:現今的處理觀念
- Cefmetazole對腹腔感染的臨床評估
- 比較社區與住院病人感染ORSA的危險因子,醫療行為與預後
- Spinal Epidural Abscesses: A Retrospective Analysis of Clinical Manifestations, Sources of Infection, and Outcomes
- 感染性動脈瘤導致腦出血之個案報告--應用「國際功能、失能和健康分類模式」分析
- 異體造血幹細胞移植後移植物抗宿主疾病所引起的皮膚病變及其護理
- Pseudomonas Aeruginosa Central Nervous System Infections: Analysis of Clinical Features of 16 Adult Patients
頁籤選單縮合
題 名 | 骨髓纖維化病患接受異體造血幹細胞移植之預後:單一中心回溯性研究=The Outcome of Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: A Retrospective Study in a Single Center |
---|---|
作 者 | 侯美芳; 侯信安; 林建廷; 李啟誠; 姚明; 莊傑仰; 林中梧; 柯博升; 黃聖懿; 周文堅; 陳耀昌; 田蕙芬; 唐季祿; | 書刊名 | 臺灣癌症醫學雜誌 |
卷 期 | 2:1 2015.03[民104.03] |
頁 次 | 頁31-41 |
分類號 | 415.6 |
關鍵詞 | 骨髓纖維化; 異體造血幹細胞移植; 感染; 預後; 移植物抗宿主疾病; Myelofibrosis; Allogeneic hematopoietic stem cell transplantation; Infection; Prognosis; Graft-versus-host disease; |
語 文 | 中文(Chinese) |
中文摘要 | 目的:異體造血幹細胞移植是唯一能根治骨髓纖維化之治療,本研究回溯分析台大醫院骨髓纖維化病患接受移植之預後。結果: 11位病患接受移植,中位年齡為 51歲,從診斷到移植的時間為 10.1個月,病患都屬中高/高度風險族群, 5位接受骨髓殲滅性化療, 6位接受減低強度療法。移植後,全部病患均轉成全捐者基因嵌合體。 3位病患移植後骨髓病理切片顯示纖維化有明顯改善。移植後 100天之移植相關致死率為 9%,4位病患發生第三至四級急性移植物抗宿主疾病。 6位病患死亡,死因包括移植物抗宿主疾病、感染、次發性移植失敗, 2年整體存活率為45.5%。結論:異體造血幹細胞移植對骨髓纖維化具有療效,但移植相關的毒性及併發症仍相對偏高;我們須積極克服移植物抗宿主疾病及感染所造成的併發症以改善病人存活。 |
英文摘要 | Purpose: Nowadays, myelofibrosis can be cured only by allogeneic hematopoietic stem cell transplantation (allo-HSCT), but the transplantation experience is very limited worldwide. We retrospectively investigated the treatment outcome of myelofibrosis patients post allo-HSCT at National Taiwan University Hospital. Results: Eleven myelofibrosis patients received allo-HSCT. The median age at transplantation was 51 years old and the median time from diagnosis to transplantation was 10.1 months. All patients were classified as intermediate-2 or high risk based on the International Prognostic Scoring System (IPSS). Conditioning regimens were myeloablative in 5 and reduced-intensity in 6 patients. All patients achieved full donor chimerism, and post-transplantation bone marrow biopsies showed significant improvement of myelofibrosis in 3 patients. The transplant-related mortality at 100 days post transplantation was 9%. Four patients had grade III-IV acute graft-versus-host disease. Six patients died, and the causes of death were GVHD (n=3), infection (n=2) and secondary graft failure (n=1). The estimated overall survival at two years was 45.5%. Conclusions: Allogeneic hematopoietic stem cell transplantation is effective in treating myelofibrosis and is associated with modest toxicity and post-transplantation complications. In order to improve the treatment outcome, we have to manage GVHD and infection more carefully. |
本系統中英文摘要資訊取自各篇刊載內容。